It is known that TLR8 activation can enhance TNF and IL-1β production, both associated with mucosal inflammation in UC [48], whereas TLR7 agonists could induce a type I IFN response and prevent experimental colitis in mice [48]. This evidence concerns the gene TNF and colitis.